Plasma extracellular vesicle circRNA signature and resistance to abiraterone in metastatic castration-resistant prostate cancer
Menée à partir d'échantillons plasmatiques prélevés sur des patients recevant un traitement de première ligne par abiratérone pour un cancer métastatique de la prostate résistant à la castration, cette étude évalue la performance d'une signature, basée sur 5 ARNs circulaires de vésicules extracellulaires (circCEP112, circFAM13A, circBRWD1, circVPS13C et circMACROD2), pour prédire la survie globale
Background : We aimed to develop and validate a plasma extracellular vesicle circular RNA (circRNA)-based signature that can predict overall survival (OS) in first-line abiraterone therapy for metastatic castration-resistant prostate cancer (mCRPC) patients.
Methods : In total, 582 mCRPC patients undergoing first-line abiraterone therapy from four institutions were sorted by three phases. In the discovery phase, 30 plasma samples from 30 case-matched patients with or without early progression were obtained to generate circRNA expression profiles using RNA sequencing. In the training phase, differentially expressed circRNAs were examined using digital droplet PCR in a training cohort (n = 203). The circRNA signature was constructed using a least absolute shrinkage and selection operator Cox regression to predict OS. In the validation phase, the prognostic ability of this signature was prospectively validated in two external cohorts (Cohort I, n = 183; Cohort II, n = 166).
Results : We developed a five-circRNA signature, based on circCEP112, circFAM13A, circBRWD1, circVPS13C and circMACROD2, which successfully stratified patients into high-risk and low-risk groups. The prognostic ability of this signature was prospectively validated in two external cohorts (P < 0.0001, P < 0.0001). Patients with high-risk scores had shorter OS than patients with low-risk scores.
Conclusion : This five-circRNA signature is a reliable predictor of OS for mCRPC patients undergoing abiraterone.
British Journal of Cancer , résumé, 2023